Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1738 entries
Sorted by: Best Match Show Resources per page
Therapy by design: evaluating the UK hospital building program

program design

Bell M, Hubbard P.
GSID: r2FnPkjjRHUJ
W Gesler, M Bell, S Curtis, P Hubbard, S Francis - Health & place, 2004 - Elsevier

A renewed interest in hospital design in the UK, prompted by the Private Finance Initiative, provides an opportunity to consider hospitals as ‘therapeutic environments’. Noting that the therapeutic value of hospitals is related to their physical, social and symbolic...

Cite
Gesler, W., Bell, M., Curtis, S., Hubbard, P., & Francis, S. (2004). Therapy by design: evaluating the UK hospital building program. Health & place, 10(2), 117-128.
Gesler, Wil, et al. "Therapy by design: evaluating the UK hospital building program." Health & place 10.2 (2004): 117-128.
Copy Download .nbib Format: MLA
Shale gas regulation in the UK and health implications of fracking.

Lancet (London, England)

Hill M.
PMID: 24954684
Lancet. 2014 Jun 28;383(9936):2211-2. doi: 10.1016/S0140-6736(14)60888-6. Epub 2014 Jun 19.

No abstract available.

Cite
Hill M. Shale gas regulation in the UK and health implications of fracking. Lancet. 2014;383(9936):2211-2doi: 10.1016/S0140-6736(14)60888-6.
Hill, M. (2014). Shale gas regulation in the UK and health implications of fracking. Lancet (London, England), 383(9936), 2211-2. https://doi.org/10.1016/S0140-6736(14)60888-6
Hill, Michael. "Shale gas regulation in the UK and health implications of fracking." Lancet (London, England) vol. 383,9936 (2014): 2211-2. doi: https://doi.org/10.1016/S0140-6736(14)60888-6
Hill M. Shale gas regulation in the UK and health implications of fracking. Lancet. 2014 Jun 28;383(9936):2211-2. doi: 10.1016/S0140-6736(14)60888-6. Epub 2014 Jun 19. PMID: 24954684.
Copy Download .nbib Format: NLM
Repeat colonoscopy after a colonoscopy with a negative result in Ontario: a population-based cohort study.

CMAJ open

Hol L, Sutradhar R, Gu S, Baxter NN, Rabeneck L, Tinmouth JM, Paszat LF.
PMID: 26389103
CMAJ Open. 2015 Apr 02;3(2):E244-50. doi: 10.9778/cmajo.20140063. eCollection 2015.

BACKGROUND: Data suggest the overuse of repeat colonoscopies, especially in patients at low risk for colorectal cancer. Our objective was to evaluate the time to repeat colonoscopies in low-risk patients aged 50-79 years old and the associated patient- and...

Cite
Hol L, Sutradhar R, Gu S, et al. Repeat colonoscopy after a colonoscopy with a negative result in Ontario: a population-based cohort study. CMAJ Open. 2015;3(2):E244-50doi: 10.9778/cmajo.20140063.
Hol, L., Sutradhar, R., Gu, S., Baxter, N. N., Rabeneck, L., Tinmouth, J. M., Paszat, L. F. (2015). Repeat colonoscopy after a colonoscopy with a negative result in Ontario: a population-based cohort study. CMAJ open, 3(2), E244-50. https://doi.org/10.9778/cmajo.20140063
Hol, Lieke, et al. "Repeat colonoscopy after a colonoscopy with a negative result in Ontario: a population-based cohort study." CMAJ open vol. 3,2 (2015): E244-50. doi: https://doi.org/10.9778/cmajo.20140063
Hol L, Sutradhar R, Gu S, Baxter NN, Rabeneck L, Tinmouth JM, Paszat LF. Repeat colonoscopy after a colonoscopy with a negative result in Ontario: a population-based cohort study. CMAJ Open. 2015 Apr 02;3(2):E244-50. doi: 10.9778/cmajo.20140063. eCollection 2015. PMID: 26389103; PMCID: PMC4565168.
Copy Download .nbib Format: NLM
An Authentication Protocol for Future Sensor Networks.

Sensors (Basel, Switzerland)

Bilal M, Kang SG.
PMID: 28452937
Sensors (Basel). 2017 Apr 28;17(5). doi: 10.3390/s17050979.

Authentication is one of the essential security services in Wireless Sensor Networks (WSNs) for ensuring secure data sessions. Sensor node authentication ensures the confidentiality and validity of data collected by the sensor node, whereas user authentication guarantees that only...

Cite
Bilal M, Kang SG. An Authentication Protocol for Future Sensor Networks. Sensors (Basel). 2017;17(5)doi: 10.3390/s17050979.
Bilal, M., & Kang, S. G. (2017). An Authentication Protocol for Future Sensor Networks. Sensors (Basel, Switzerland), 17(5), . https://doi.org/10.3390/s17050979
Bilal, Muhammad, and Kang, Shin-Gak. "An Authentication Protocol for Future Sensor Networks." Sensors (Basel, Switzerland) vol. 17,5 (2017). doi: https://doi.org/10.3390/s17050979
Bilal M, Kang SG. An Authentication Protocol for Future Sensor Networks. Sensors (Basel). 2017 Apr 28;17(5). doi: 10.3390/s17050979. PMID: 28452937; PMCID: PMC5464775.
Copy Download .nbib Format: NLM
Macrocyclization in the Design of Organic n-Type Electronic Materials.

Journal of the American Chemical Society

Ball M, Zhong Y, Fowler B, Zhang B, Li P, Etkin G, Paley DW, Decatur J, Dalsania AK, Li H, Xiao S, Ng F, Steigerwald ML, Nuckolls C.
PMID: 27666433
J Am Chem Soc. 2016 Oct 05;138(39):12861-12867. doi: 10.1021/jacs.6b05474. Epub 2016 Sep 26.

Here, we compare analogous cyclic and acyclic π-conjugated molecules as n-type electronic materials and find that the cyclic molecules have numerous benefits in organic photovoltaics. This is the first report of such a direct comparison. We designed two conjugated...

Cite
Ball M, Zhong Y, Fowler B, et al. Macrocyclization in the Design of Organic n-Type Electronic Materials. J Am Chem Soc. 2016;138(39):12861-12867doi: 10.1021/jacs.6b05474.
Ball, M., Zhong, Y., Fowler, B., Zhang, B., Li, P., Etkin, G., Paley, D. W., Decatur, J., Dalsania, A. K., Li, H., Xiao, S., Ng, F., Steigerwald, M. L., & Nuckolls, C. (2016). Macrocyclization in the Design of Organic n-Type Electronic Materials. Journal of the American Chemical Society, 138(39), 12861-12867. https://doi.org/10.1021/jacs.6b05474
Ball, Melissa, et al. "Macrocyclization in the Design of Organic n-Type Electronic Materials." Journal of the American Chemical Society vol. 138,39 (2016): 12861-12867. doi: https://doi.org/10.1021/jacs.6b05474
Ball M, Zhong Y, Fowler B, Zhang B, Li P, Etkin G, Paley DW, Decatur J, Dalsania AK, Li H, Xiao S, Ng F, Steigerwald ML, Nuckolls C. Macrocyclization in the Design of Organic n-Type Electronic Materials. J Am Chem Soc. 2016 Oct 05;138(39):12861-12867. doi: 10.1021/jacs.6b05474. Epub 2016 Sep 26. PMID: 27666433.
Copy Download .nbib Format: NLM
Geoffrey Munro Gill.

BMJ (Clinical research ed.)

Gill M, Fouin P.
PMID: 28455427
BMJ. 2017 Apr 28;357:j2038. doi: 10.1136/bmj.j2038.

No abstract available.

Cite
Gill M, Fouin P. Geoffrey Munro Gill. BMJ. 2017;357:j2038doi: 10.1136/bmj.j2038.
Gill, M., & Fouin, P. (2017). Geoffrey Munro Gill. BMJ (Clinical research ed.), 357j2038. https://doi.org/10.1136/bmj.j2038
Gill, Margaret, and Fouin, Pierre. "Geoffrey Munro Gill." BMJ (Clinical research ed.) vol. 357 (2017): j2038. doi: https://doi.org/10.1136/bmj.j2038
Gill M, Fouin P. Geoffrey Munro Gill. BMJ. 2017 Apr 28;357:j2038. doi: 10.1136/bmj.j2038. PMID: 28455427.
Copy Download .nbib Format: NLM
Cannabis use and treatment resistance in first episode psychosis: a natural language processing study.

Lancet (London, England)

Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M, Stewart R, McGuire P, Bhattacharyya S.
PMID: 26312901
Lancet. 2015 Feb 26;385:S79. doi: 10.1016/S0140-6736(15)60394-4.

BACKGROUND: Cannabis is frequently used among individuals with first episode psychosis and is associated with poor clinical outcomes. However, little is known about the effect of cannabis use on the response to antipsychotic medications and how use could affect...

Cite
Patel R, Wilson R, Jackson R, et al. Cannabis use and treatment resistance in first episode psychosis: a natural language processing study. Lancet. 2015;385:S79doi: 10.1016/S0140-6736(15)60394-4.
Patel, R., Wilson, R., Jackson, R., Ball, M., Shetty, H., Broadbent, M., Stewart, R., McGuire, P., & Bhattacharyya, S. (2015). Cannabis use and treatment resistance in first episode psychosis: a natural language processing study. Lancet (London, England), 385S79. https://doi.org/10.1016/S0140-6736(15)60394-4
Patel, Rashmi, et al. "Cannabis use and treatment resistance in first episode psychosis: a natural language processing study." Lancet (London, England) vol. 385 (2015): S79. doi: https://doi.org/10.1016/S0140-6736(15)60394-4
Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M, Stewart R, McGuire P, Bhattacharyya S. Cannabis use and treatment resistance in first episode psychosis: a natural language processing study. Lancet. 2015 Feb 26;385:S79. doi: 10.1016/S0140-6736(15)60394-4. PMID: 26312901.
Copy Download .nbib Format: NLM
Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria.

Journal of clinical and diagnostic research : JCDR

Goyal V, Gupta A, Gupta O, Lal D, Gill M.
PMID: 28511488
J Clin Diagn Res. 2017 Mar;11(3):WC06-WC09. doi: 10.7860/JCDR/2017/23961.9550. Epub 2017 Mar 01.

INTRODUCTION: Acute and chronic urticaria can result in severely impaired quality of life from pruritus and associated sleep lessness, as well as anxiety and depression. Various treatment modalities are available out of which second generation non sedating H1 antihistamines...

Cite
Goyal V, Gupta A, Gupta O, et al. Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria. J Clin Diagn Res. 2017;11(3):WC06-WC09doi: 10.7860/JCDR/2017/23961.9550.
Goyal, V., Gupta, A., Gupta, O., Lal, D., & Gill, M. (2017). Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria. Journal of clinical and diagnostic research : JCDR, 11(3), WC06-WC09. https://doi.org/10.7860/JCDR/2017/23961.9550
Goyal, Vippan, et al. "Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria." Journal of clinical and diagnostic research : JCDR vol. 11,3 (2017): WC06-WC09. doi: https://doi.org/10.7860/JCDR/2017/23961.9550
Goyal V, Gupta A, Gupta O, Lal D, Gill M. Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria. J Clin Diagn Res. 2017 Mar;11(3):WC06-WC09. doi: 10.7860/JCDR/2017/23961.9550. Epub 2017 Mar 01. PMID: 28511488; PMCID: PMC5427414.
Copy Download .nbib Format: NLM
A Case of Early Disseminated Neurological Lyme Disease Followed by Atypical Cutaneous Manifestations.

Case reports in infectious diseases

Kantamaneni V, Sunder V, Bilal M, Vargo S.
PMID: 28512589
Case Rep Infect Dis. 2017;2017:6598043. doi: 10.1155/2017/6598043. Epub 2017 Apr 23.

Lyme disease (LD) is a tick-borne illness caused by

Cite
Kantamaneni V, Sunder V, Bilal M, et al. A Case of Early Disseminated Neurological Lyme Disease Followed by Atypical Cutaneous Manifestations. Case Rep Infect Dis. 2017;2017:6598043doi: 10.1155/2017/6598043.
Kantamaneni, V., Sunder, V., Bilal, M., & Vargo, S. (2017). A Case of Early Disseminated Neurological Lyme Disease Followed by Atypical Cutaneous Manifestations. Case reports in infectious diseases, 20176598043. https://doi.org/10.1155/2017/6598043
Kantamaneni, Vamsi, et al. "A Case of Early Disseminated Neurological Lyme Disease Followed by Atypical Cutaneous Manifestations." Case reports in infectious diseases vol. 2017 (2017): 6598043. doi: https://doi.org/10.1155/2017/6598043
Kantamaneni V, Sunder V, Bilal M, Vargo S. A Case of Early Disseminated Neurological Lyme Disease Followed by Atypical Cutaneous Manifestations. Case Rep Infect Dis. 2017;2017:6598043. doi: 10.1155/2017/6598043. Epub 2017 Apr 23. PMID: 28512589; PMCID: PMC5420423.
Copy Download .nbib Format: NLM
Lipid transport and epithelial barrier integrity.

Oncotarget

Fritz JM, Yang L, Weaver TE.
PMID: 26309076
Oncotarget. 2015 Aug 28;6(25):20744-5. doi: 10.18632/oncotarget.5233.

No abstract available.

Cite
Fritz JM, Yang L, Weaver TE. Lipid transport and epithelial barrier integrity. Oncotarget. 2015;6(25):20744-5doi: 10.18632/oncotarget.5233.
Fritz, J. M., Yang, L., & Weaver, T. E. (2015). Lipid transport and epithelial barrier integrity. Oncotarget, 6(25), 20744-5. https://doi.org/10.18632/oncotarget.5233
Fritz, Jill M, et al. "Lipid transport and epithelial barrier integrity." Oncotarget vol. 6,25 (2015): 20744-5. doi: https://doi.org/10.18632/oncotarget.5233
Fritz JM, Yang L, Weaver TE. Lipid transport and epithelial barrier integrity. Oncotarget. 2015 Aug 28;6(25):20744-5. doi: 10.18632/oncotarget.5233. PMID: 26309076; PMCID: PMC4673222.
Copy Download .nbib Format: NLM
Validation of a blood protein signature for non-small cell lung cancer.

Clinical proteomics

Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, Pass HI, Rom WN, Muley T, Meister M, Franklin W, Miller YE, Brody EN, Ostroff RM.
PMID: 25114662
Clin Proteomics. 2014 Aug 01;11(1):32. doi: 10.1186/1559-0275-11-32. eCollection 2014.

BACKGROUND: CT screening for lung cancer is effective in reducing mortality, but there are areas of concern, including a positive predictive value of 4% and development of interval cancers. A blood test that could manage these limitations would be...

Cite
Mehan MR, Williams SA, Siegfried JM, et al. Validation of a blood protein signature for non-small cell lung cancer. Clin Proteomics. 2014;11(1):32doi: 10.1186/1559-0275-11-32.
Mehan, M. R., Williams, S. A., Siegfried, J. M., Bigbee, W. L., Weissfeld, J. L., Wilson, D. O., Pass, H. I., Rom, W. N., Muley, T., Meister, M., Franklin, W., Miller, Y. E., Brody, E. N., & Ostroff, R. M. (2014). Validation of a blood protein signature for non-small cell lung cancer. Clinical proteomics, 11(1), 32. https://doi.org/10.1186/1559-0275-11-32
Mehan, Michael R, et al. "Validation of a blood protein signature for non-small cell lung cancer." Clinical proteomics vol. 11,1 (2014): 32. doi: https://doi.org/10.1186/1559-0275-11-32
Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, Pass HI, Rom WN, Muley T, Meister M, Franklin W, Miller YE, Brody EN, Ostroff RM. Validation of a blood protein signature for non-small cell lung cancer. Clin Proteomics. 2014 Aug 01;11(1):32. doi: 10.1186/1559-0275-11-32. eCollection 2014. PMID: 25114662; PMCID: PMC4123246.
Copy Download .nbib Format: NLM
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.

Open forum infectious diseases

Mulligan MJ, Bernstein DI, Frey S, Winokur P, Rouphael N, Dickey M, Edupuganti S, Spearman P, Anderson E, Graham I, Noah DL, Mangal B, Kim S, Hill H, Whitaker J, Emery W, Beck A, Stephens K, Hartwell B, Ogilvie M, Rimann N, Osinski E, Destefano E, Gajadhar T, Strudwick A, Pierce K, Lai L, Yue L, Wang D, Ying C, Cline A, Foltz T, Wagner N, Dull G, Pacatte T, Taggart B, Johnson V, Haller L, Looney C, Li S, May M, Myers B, May R, Parker L, Cochran N, Bowen D, Bell M, Scoggins J, Burns A, Stablein C, Wolff M, Jolles B, Leung B, Lambert L, Shorer S, Buchanan W, Murray S, Chang S, Gorman R.
PMID: 25734170
Open Forum Infect Dis. 2014 Nov 18;1(3):ofu102. doi: 10.1093/ofid/ofu102. eCollection 2014 Dec.

BACKGROUND: Avian influenza A/H5N1 has threatened human health for nearly 2 decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for mass vaccination will be needed if a pandemic occurs.METHODS: A multicenter, randomized, blinded...

Cite
Mulligan MJ, Bernstein DI, Frey S, et al. Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open Forum Infect Dis. 2014;1(3):ofu102doi: 10.1093/ofid/ofu102.
Mulligan, M. J., Bernstein, D. I., Frey, S., Winokur, P., Rouphael, N., Dickey, M., Edupuganti, S., Spearman, P., Anderson, E., Graham, I., Noah, D. L., Mangal, B., Kim, S., Hill, H., Whitaker, J., Emery, W., Beck, A., Stephens, K., Hartwell, B., Ogilvie, M., Rimann, N., Osinski, E., Destefano, E., Gajadhar, T., Strudwick, A., Pierce, K., Lai, L., Yue, L., Wang, D., Ying, C., Cline, A., Foltz, T., Wagner, N., Dull, G., Pacatte, T., Taggart, B., Johnson, V., Haller, L., Looney, C., Li, S., May, M., Myers, B., May, R., Parker, L., Cochran, N., Bowen, D., Bell, M., Scoggins, J., Burns, A., Stablein, C., Wolff, M., Jolles, B., Leung, B., Lambert, L., Shorer, S., Buchanan, W., Murray, S., Chang, S., & Gorman, R. (2014). Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open forum infectious diseases, 1(3), ofu102. https://doi.org/10.1093/ofid/ofu102
Mulligan, Mark J, et al. "Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial." Open forum infectious diseases vol. 1,3 (2014): ofu102. doi: https://doi.org/10.1093/ofid/ofu102
Mulligan MJ, Bernstein DI, Frey S, Winokur P, Rouphael N, Dickey M, Edupuganti S, Spearman P, Anderson E, Graham I, Noah DL, Mangal B, Kim S, Hill H, Whitaker J, Emery W, Beck A, Stephens K, Hartwell B, Ogilvie M, Rimann N, Osinski E, Destefano E, Gajadhar T, Strudwick A, Pierce K, Lai L, Yue L, Wang D, Ying C, Cline A, Foltz T, Wagner N, Dull G, Pacatte T, Taggart B, Johnson V, Haller L, Looney C, Li S, May M, Myers B, May R, Parker L, Cochran N, Bowen D, Bell M, Scoggins J, Burns A, Stablein C, Wolff M, Jolles B, Leung B, Lambert L, Shorer S, Buchanan W, Murray S, Chang S, Gorman R. Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open Forum Infect Dis. 2014 Nov 18;1(3):ofu102. doi: 10.1093/ofid/ofu102. eCollection 2014 Dec. PMID: 25734170; PMCID: PMC4324215.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1738 entries